We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info . X close

Latent TB Testing Market: Growth, Size, Share, and Trends

Report Code MD 9207
Published in Feb, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Latent TB Testing Market by Test Type (Tuberculin Skin Test/TST, IGRA Test), Application (Household Contacts (HHC) of Tuberculosis (TB) Patients, People Living with HIV), End User (Diagnostic Labs, Hospitals), Region - Global Forecast to 2029

Updated on : February 7, 2025

Overview

It is estimated that the latent TB testing market will grow from USD 582.5 million in 2024 to around USD 773.4 million in 2029 at a CAGR of 5.8% during the forecast period. The major drivers of the market include the rising prevalence of latent TB, especially among the high-risk populations that include immunocompromised individuals as well as people coming from the high TB incidence regions. The market further receives support with increasing investments made by government agencies, international health organizations, and funding initiatives. As a result, these organizations' commitment to TB eradication has made latent TB testing market grow significantly with advanced diagnostic technologies and easy access to testing facilities. Therefore, the latent TB testing market will experience steady growth in the coming years.

Latent TB Testing Market– Global Forecast and Key Opportunities to 2029

Attractive Opportunities in the Latent TB Testing Market

Asia Pacific

Market growth in the Asia Pacific can be attributed to the rising incidence of tuberculosis, increasing healthcare expenditure and rapid expansion of medical infrastructure.

The market is driven by the growing prevalence of latent tuberculosis globally and increasing funding from international organizations and governments for TB control programs.

Countries like India and South Africa have high TB prevalence rates and increasing healthcare investments, creating a substantial demand for effective latent TB tests.

The Asia Pacific latent TB testing market is expected to be worth USD 298.7 million by 2029, growing at CAGR of 8.1% during the forecast period.

Product approvals and partnerships were the most widely adopted growth strategies by market players.

Global Latent TB Testing Market Dynamics

DRIVER: Increased incidence of latent TB worldwide

Latent TB infections (LTBI) are emerging as one of the biggest challenges to public health. Most newly acquired cases of TB emerge from those with LTBI, making detection and treatment of these latent infections very important for public health. The risk has also increased for latent developing into active TB due to the increasing population of immunocompromised individuals, mainly attributed to conditions like HIV. Growing number of active cases of TB leads to the demand for adequate screening and prompt treatment as significant steps toward controlling TB worldwide. For this reason, public health initiatives are increasingly focusing on treating latent TB infections to prevent progression to active TB. Latent TB testing is in high demand and has become a key priority in global efforts to control TB.

RESTRAINT: Unfavourable reimbursement landscape

Reimbursement policies are one key factor hindering the growth of the latent TB testing market. Most diagnostic firms find it difficult to pursue commercialization of their tests due to challenges in receiving favorable coverage from insurers either in the public or private sector. Problems arise when tests lack specific codes, often leading to inconsistent reimbursement systems where local health authorities or insurance administrators set their own rates. Besides, several countries have changed their reimbursement systems, which has increased pressure on clinical laboratories since some tests face low remunerations. In some regions, diagnostic testing has had significant cuts in reimbursement over the past decades, and budgetary restrictions in healthcare systems have further been an issue in the adoption of new diagnostic technologies. Such financial issues further constrain the growth of the market and may postpone patient access to better diagnostics, which is a strong limitation in the latent TB testing market worldwide.

 

OPPORTUNITY: Opportunities for growth in developing economies

Emerging markets like India, Brazil, Turkey, Russia, and South Africa may provide growth opportunities for major latent TB testing market players. This is because of factors such as the high prevalence of TB, large patient base, improved healthcare infrastructure, and rising disposable income. Added to the above factors, the Asia Pacific region has become an adaptive and business-friendly hub with relatively less stringent regulations and data requirements. The upgrading laboratory infrastructures of these countries have been well represented by the high investments in healthcare and life science research in emerging markets. This supports the establishment of diagnostic systems in laboratories and results in increased use of sophisticated diagnostic technologies. Additionally, increasing awareness of the need for early disease diagnosis in developing markets, along with the growing healthcare spending in these countries will further drive the demand for latent TB assay kits and equipment.

CHALLENGES: Operational constraints and labor gap

Clinical labs in key markets are undergoing massive operational challenges as they adapt to the changing landscape. Often, it becomes challenging for the technicians when the collection, storage, and transport of samples are involved, especially when new technologies such as IGRAs for latent TB are integrated. Hence, specific diagnostic tests require redesigning setups in laboratories to minimize cross-contamination risks and enhance process efficiency. These incidental changes can increase operation costs as end users focus on using high-end diagnostic equipment, especially when designed for only one sample type. Furthermore, frequent epidemic outbreaks force labs to invest in advanced technologies for faster and more accurate diagnosis. However, a lack of skilled technicians, especially in emerging markets, prevents the effective utilization of these technologies. These operational and workforce issues might prevent the incorporation of new diagnostic solutions, thereby limiting market growth.

Global Latent TB Testing Market Ecosystem Analysis

The latent TB testing market thrives on a complex ecosystem. It includes test types, including TSTs and IGRAs that diagnostic labs, hospitals, and research institutes use. The manufacturers focus on the design and optimization of the tests. Distributors include third-party vendors as well as e-commerce platforms. The key stakeholders include the high-risk populations being diagnosed, the investors, and the regulatory bodies.

Latent TB Testing Market Ecosystem
 

The interferon gamma release assay (IGRA) segment accounted for the largest share of the market in 2023, by test type

The latent TB testing market can be segmented based on test type into tuberculin skin test (TST) and interferon gamma release assay (IGRA). In 2023, the market was dominated by the IGRA segment because of its much better specificity and sensitivity as compared to TST. This accuracy is very important for people who have already been exposed to TB or have weakened immune systems, as it is crucial for proper treatment. Another advantage of IGRA tests is that, compared with the need for a return visit for reading results in the case of TST, only a single patient visit is needed to collect blood. This comfort implies better compliance among patients, and overall, the process becomes easier for healthcare providers.

Diagnostic laboratories segment dominated the latent TB testing market in 2023, based on end user

The latent TB testing market is categorized into diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users. In 2023, diagnostic laboratories accounted for the largest market share. These labs have the advanced technologies and adequately trained personnel to conduct a variety of tests for the diagnosis of latent TB and help prevent its progression to active tuberculosis. Increasing prevalence of tuberculosis all around the world creates huge volumes of patients needing to be tested, which translates into diagnostic labs becoming vital within the network of healthcare providers. Furthermore, the advancements in laboratory technologies and the need to reduce turnaround times of these tests make healthcare providers primarily depend on diagnostic labs. Collectively, these factors boost the prominence of diagnostic laboratories as the largest end- user segment.

In 2023, North America held the largest share of the latent TB testing market.

The market for latent TB testing has been segmented into five major geographical regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America was at the forefront of the market in 2023. This is due to the rising cases of latent TB in some demographics, such as people suffering from compromised immune systems, those directly in contact with patients suffering from TB, immigrants, and healthcare professionals. Advanced testing technologies have been implemented widely in the region due to the well-established and advanced healthcare infrastructure, which has good diagnostic laboratories and extensive access to healthcare services for timely and accurate diagnoses. In addition, strong regulatory frameworks make testing services more accessible and affordable, thereby promoting the adoption of newer, more advanced technologies by healthcare providers. Public health efforts toward TB control and prevention, combined with growing awareness of the importance of early detection and treatment, further support the growth of latent TB testing in the region.

HIGHEST CAGR MARKET IN 2023
US FASTEST GROWING MARKET IN THE REGION
Latent TB Testing Market Region

Recent Developments of Latent TB Testing Market

  • In April 2024, Revvity (US) launched the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The use of the Auto-Pure 2400 platform with the T-SPOT.TB test will provide labs with an efficient workflow, allowing latent TB testing to be run in mid-high-volume settings.
  • In March 2024, QIAGEN (Netherlands) announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest TB screening requirements, with a special focus on the IGRA requirements and the associated benefits for patients and healthcare providers.
  • In February 2023, QIAGEN’s (Netherlands) TB blood test QuantiFERON-TB Gold Plus gained the CE Mark under the EU’s 2017/746 In Vitro Diagnostic Medical Devices Regulation (IVDR), which replaced the 98/79/EC In Vitro Diagnostic Directive (IVDD).
  • In December 2022, bioMérieux (France) announced the CE-marking of VIDAS KUBE, a next generation automated immunoassay system for the VIDAS assay range, including the VIDAS TB-IGRA test for latent TB. This innovation benefits clinical labs by providing results to help speed up patient care and protect consumers.

Key Market Players

Want to explore hidden markets that can drive new revenue in Latent TB Testing Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Value (USD) and Volume (Millions)
Segments covered Test Type, Application, and End User
Geographies covered North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Key Questions Addressed by the Report

Recent trends in latent TB testing trends show adoption of advanced diagnostic technologies like the interferon-gamma release assays, favored for their superior accuracy and convenience, along with growth in TB screening programs in high-burden countries with huge investments in research and development for innovative diagnostics. An added reason is the increasing interest in early detection, especially among high-risk groups, which will increase demand for better latent TB testing solutions.
Based on test type, the latent TB testing market can broadly be divided into tuberculin skin test (TST) and interferon gamma release assay (IGRA). The IGRA test segment dominates the market due to its relatively higher accuracy, sensitivity, and specificity over the traditional tuberculin skin test (TST). IGRA can be conducted within a single patient visit, which is more convenient and enhances compliance among the patients. It also provides more precise results in the immunocompromised population and those who have been previously vaccinated with BCG.
The key players in this market are QIAGEN (Netherlands), Revvity (US), Beijing Wantai Biopharmaceutical (China), Sanofi (France), Endo (US), bioMérieux (France), SD Biosensor (South Korea), Lionex (Germany), Serum Institute of India (India), ARKRAY (Japan), Zhi Fei Biological (China), AID Autoimmun Diagnostika (Germany), Boditech Med (South Korea), invitros (South Korea), Bioneovan (China), and Biopanda Reagents (UK).
The latent TB testing market is bifurcated into household contacts with pulmonary TB, people living with HIV, and other applications. People living with HIV are the largest application segment in the latent TB testing market as they have a much greater chance of developing active TB because of their weakened overall immunity due to HIV. Early detection of latent TB in PLHIV can prevent its activation, which can prove fatal in such immunocompromised patients. Consequently, latent TB screening has now become an integral part of HIV treatment management, thus increasing the demand for effective and precise testing solutions. Simultaneously, the rising international efforts along with WHO guidelines focused on TB screening among PLHIV accelerate the growth in this segment.
The Asia Pacific region is one of the most promising regions in the latent TB testing market, primarily due to the high prevalence of tuberculosis, the large patient population, and the advanced infrastructure for healthcare.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Latent TB Testing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
25
RESEARCH METHODOLOGY
29
EXECUTIVE SUMMARY
42
PREMIUM INSIGHTS
46
MARKET OVERVIEW
49
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Rising incidence of latent tuberculosis
    - Widespread use of BCG vaccine
    - Increased funding and grants for TB control programs
    RESTRAINTS
    - Unfavorable reimbursement scenario
    OPPORTUNITIES
    - Growth opportunities in emerging economies
    CHALLENGES
    - Changing regulatory landscape
    - Operational barriers and labor shortage
  • 5.3 PRICING ANALYSIS
    AVERAGE SELLING PRICE, BY PRODUCT
    INDICATIVE PRICE OF IGRA TESTS, BY REGION
  • 5.4 PATENT ANALYSIS
    LIST OF MAJOR PATENTS
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 TRADE ANALYSIS
    IMPORT DATA
    EXPORT DATA
  • 5.8 ECOSYSTEM ANALYSIS
    ROLE IN ECOSYSTEM
  • 5.9 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF BUYERS
    BARGAINING POWER OF SUPPLIERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA
  • 5.11 REGULATORY ANALYSIS
    REGULATORY LANDSCAPE
    - North America
    - Europe
    - Asia Pacific
    - Latin America
    - Middle East
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    - North America
    - Europe
    - Asia Pacific
    - Latin America
    - Rest of the world
  • 5.12 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Tuberculin skin test
    COMPLEMENTARY TECHNOLOGIES
    - Interferon gamma release assay
  • 5.13 KEY CONFERENCES AND EVENTS, 2024–2025
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.15 INVESTMENT & FUNDING SCENARIO
  • 5.16 CASE STUDY ANALYSIS
    CASE STUDY 1: EXPLORING CYTOKINE USAGE IN MONITORING LTBI TREATMENT
    CASE STUDY 2: ASSESSING DIAGNOSTIC ACCURACY OF ESAT6-CFP10 (EC) SKIN TEST FOR LTBI DETECTION
    CASE STUDY 3: EVALUATING MTB-SPECIFIC CYTOKINE RESPONSES FOR ENHANCED LTBI DETECTION IN HEU INFANTS
  • 5.17 LATENT TB CONTROL STRATEGIES IN MAJOR COUNTRIES
    NORTH AMERICA
    - US
    - Canada
    EUROPE
    - Germany
    - UK
    ASIA PACIFIC
    - Japan
    - China
    - India
    - Singapore
  • 5.18 IMPACT OF AI ON LATENT TB TESTING MARKET
    KEY USE CASES
LATENT TB TESTING MARKET, BY TEST TYPE
90
  • 6.1 INTRODUCTION
  • 6.2 IGRA
    HIGHER SPECIFICITY AND ACCURACY TO BOOST MARKET SEGMENT
  • 6.3 TST
    COST-EFFECTIVENESS TO PROPEL MARKET GROWTH
LATENT TB TESTING MARKET, BY APPLICATION
101
  • 7.1 INTRODUCTION
  • 7.2 PEOPLE LIVING WITH HIV
    RISING RATES OF TB-HIV COINFECTION TO PROPEL GROWTH
  • 7.3 HOUSEHOLD CONTACTS (HHC) WITH PULMONARY TUBERCULOSIS (TB)/ HOUSEHOLD CONTACTS (HHC) OF TUBERCULOSIS (TB) PATIENTS
    NEED FOR ROUTINE SCREENING FOR HOUSEHOLD CONTACTS TO BOOST SEGMENT
  • 7.4 OTHER APPLICATIONS
LATENT TB TESTING MARKET, BY END USER
115
  • 8.1 INTRODUCTION
  • 8.2 DIAGNOSTIC LABORATORIES
    WELL-DEVELOPED INFRASTRUCTURE AND CAPABILITIES TO SUPPORT DEMAND FOR TESTING METHODS
  • 8.3 HOSPITALS & CLINICS
    GROWING NUMBER OF HOSPITALS AND GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT
  • 8.4 ACADEMIC & RESEARCH INSTITUTES
    RISING INDUSTRY-ACADEMIA COLLABORATIONS TO SUPPORT MARKET GROWTH
  • 8.5 OTHER END USERS
LATENT TB TESTING MARKET, BY REGION
131
  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    NORTH AMERICA: MACROECONOMIC OUTLOOK
    US
    - US to dominate North American latent TB testing market
    CANADA
    - Improved screening and treatment for latent TB to drive market
  • 9.3 ASIA PACIFIC
    ASIA PACIFIC: MACROECONOMIC OUTLOOK
    CHINA
    - Growing public access to modern healthcare to fuel market growth
    JAPAN
    - Presence of universal healthcare reimbursement policy to drive market
    INDIA
    - High TB burden and growing government initiatives to drive demand for latent TB screening
    SOUTH KOREA
    - Rising healthcare spending in innovative diagnostic technologies to support market growth
    AUSTRALIA
    - Diverse immigrant population to fuel demand for latent TB screening
    SINGAPORE
    - Enhanced healthcare infrastructure to propel market growth
    BANGLADESH
    - Improving healthcare infrastructure to spur market growth
    REST OF ASIA PACIFIC
  • 9.4 EUROPE
    EUROPE: MACROECONOMIC OUTLOOK
    UK
    - Growing number of diagnostic centers to fuel market
    FRANCE
    - Presence of robust healthcare system to augment market growth
    GERMANY
    - Higher healthcare spending and favorable government policies to favor market growth
    SPAIN
    - Improving healthcare infrastructure to drive demand
    ITALY
    - Improved quality of medical care to spur market growth
    BELGIUM
    - Targeted screening for high-risk groups to fuel demand
    RUSSIA
    - Russia’s exclusion from WHO list of high TB burden countries to affect demand
    SWEDEN
    - Growing immigrant population from high-prevalence regions to propel demand
    DENMARK
    - Importance of latent TB testing in public health strategy to support market growth
    REST OF EUROPE
  • 9.5 LATIN AMERICA
    LATIN AMERICA: MACROECONOMIC OUTLOOK
    BRAZIL
    - Developed public health systems and improving healthcare infrastructure to favor market growth
    MEXICO
    - Modernization of healthcare infrastructure to augment market growth
    REST OF LATIN AMERICA
  • 9.6 MIDDLE EAST & AFRICA
    MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
    SOUTH AFRICA
    - Rising government initiatives for TB screening to augment market growth
    SAUDI ARABIA
    - Enhancements in healthcare infrastructure to support market growth
    UAE
    - UAE ranks among the world’s leading countries with low TB rates
    KUWAIT
    - Expansion of healthcare infrastructure to augment market growth
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
214
  • 10.1 INTRODUCTION
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LATENT TB TESTING MARKET
  • 10.3 REVENUE SHARE ANALYSIS
  • 10.4 MARKET SHARE ANALYSIS
    MARKET SHARE ANALYSIS, BY REGION
    - North America
    - Europe
    - Asia Pacific
  • 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Test type footprint
    - Application footprint
    - Region footprint
  • 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
  • 10.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, 2023
  • 10.8 VALUATION & FINANCIAL METRICS
  • 10.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
    QIAGEN
    REVVITY
    BIOMÉRIEUX
  • 10.10 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES
    DEALS
COMPANY PROFILES
231
  • 11.1 KEY PLAYERS
    QIAGEN
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    REVVITY (OXFORD IMMUNOTEC)
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    BEIJING WANTAI BIOPHARMACEUTICAL CO., LTD.
    - Business overview
    - Products offered
    - MnM view
    SANOFI
    - Business overview
    - MnM view
    ENDO, INC.
    - Business overview
    - Products offered
    - MnM view
    BIOMÉRIEUX
    - Business overview
    - Products offered
    - Recent developments
    SD BIOSENSOR, INC.
    - Business overview
    - Products offered
    - Recent developments
    LIONEX GMBH
    - Business overview
    - Products offered
    SERUM INSTITUTE OF INDIA PVT. LTD.
    - Business overview
    - Products offered
    ARKRAY, INC.
    - Business overview
    - Products offered
    - Recent developments
  • 11.2 OTHER PLAYERS
    ZHI FEI BIOLOGICAL
    AID AUTOIMMUN DIAGNOSTIKA GMBH
    BODITECH MED INC.
    BIONEOVAN CO., LTD.
    BIOPANDA REAGENTS LTD.
APPENDIX
258
  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 LATENT TB TESTING MARKET: RISK ASSESSMENT
  • TABLE 2 COMMERCIALLY AVAILABLE IGRA TESTS, BY KEY PLAYER
  • TABLE 3 AVERAGE SELLING PRICE OF LATENT TB TESTS, 2022–2024
  • TABLE 4 INDICATIVE PRICE OF IGRA TESTS, BY REGION, 2022–2024
  • TABLE 5 LATENT TB TESTING MARKET: LIST OF MAJOR PATENTS, 2022–2023
  • TABLE 6 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 7 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 8 LATENT TB TESTING MARKET: ROLE IN ECOSYSTEM
  • TABLE 9 LATENT TB TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LATENT TB TESTS (%)
  • TABLE 11 KEY BUYING CRITERIA FOR LATENT TB TESTS, BY TYPE
  • TABLE 12 CLASSIFICATION OF DEVICES IN EUROPE
  • TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 14 AUSTRALIA: CLASSIFICATION OF IVD MEDICAL DEVICES
  • TABLE 15 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 LATENT TB TESTING MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS
  • TABLE 21 LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 22 LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 23 BCG VACCINATION COVERAGE, BY REGION, 2021 VS 2022 VS 2023 (%)
  • TABLE 24 COMMERCIALLY AVAILABLE IGRA PRODUCTS, BY COMPANY
  • TABLE 25 LATENT TB TESTING MARKET FOR IGRA, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 26 NORTH AMERICA: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 27 EUROPE: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 28 ASIA PACIFIC: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 29 LATIN AMERICA: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 30 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 31 COMMERCIALLY AVAILABLE TST PRODUCTS IN MARKET, BY COMPANY
  • TABLE 32 LATENT TB TESTING MARKET FOR TST, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 33 NORTH AMERICA: LATENT TB TESTING MARKET FOR TST, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 34 EUROPE: LATENT TB TESTING MARKET FOR TST, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: LATENT TB TESTING MARKET FOR TST, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 36 LATIN AMERICA: LATENT TB TESTING MARKET FOR TST, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 37 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR TST, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 38 LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 39 LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 40 NORTH AMERICA: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 41 EUROPE: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 42 ASIA PACIFIC: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 43 LATIN AMERICA: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 44 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 45 LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 46 NORTH AMERICA: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 47 EUROPE: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 48 ASIA PACIFIC: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 49 LATIN AMERICA: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 50 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 52 NORTH AMERICA: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 53 EUROPE: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 54 ASIA PACIFIC: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 55 LATIN AMERICA: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 56 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 57 LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 58 LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 59 NORTH AMERICA: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 60 EUROPE: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 62 LATIN AMERICA: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 63 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 64 US: NUMBER OF COMMUNITY HOSPITALS, 2020 –VS 2021
  • TABLE 65 LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 66 NORTH AMERICA: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 67 EUROPE: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 68 ASIA PACIFIC: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 69 LATIN AMERICA: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 70 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 71 LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 72 NORTH AMERICA: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 73 EUROPE: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 74 ASIA PACIFIC: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 75 LATIN AMERICA: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 76 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 77 LATENT TB TESTING MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 78 NORTH AMERICA: LATENT TB TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 79 EUROPE: LATENT TB TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: LATENT TB TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 81 LATIN AMERICA: LATENT TB TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 82 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 83 LATENT TB TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 84 NORTH AMERICA: MACROINDICATORS FOR LATENT TB TESTING MARKET
  • TABLE 85 NORTH AMERICA: LATENT TB TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 87 NORTH AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 88 NORTH AMERICA: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 89 NORTH AMERICA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 90 US: MAIN TB/LTBI INSTITUTIONS
  • TABLE 91 US: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 92 US: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 93 US: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 94 US: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 95 CANADA: MAIN TB/LTBI INSTITUTIONS
  • TABLE 96 CANADA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 97 CANADA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 98 CANADA: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 99 CANADA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 100 ASIA PACIFIC: MACROECONOMIC INDICATORS FOR LATENT TB TESTING MARKET
  • TABLE 101 ASIA PACIFIC: LATENT TB TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 104 ASIA PACIFIC: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 106 CHINA: MAIN TB/LTBI INSTITUTIONS
  • TABLE 107 CHINA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 108 CHINA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 109 CHINA: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 110 CHINA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 111 JAPAN: MAIN TB/LTBI INSTITUTIONS
  • TABLE 112 JAPAN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 113 JAPAN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 114 JAPAN: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 115 JAPAN: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 116 INDIA: MAIN TB/LTBI INSTITUTIONS
  • TABLE 117 INDIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 118 INDIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 119 INDIA: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 120 INDIA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 121 SOUTH KOREA: MAIN TB/LTBI INSTITUTIONS
  • TABLE 122 SOUTH KOREA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 123 SOUTH KOREA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 124 SOUTH KOREA: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 125 SOUTH KOREA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 126 AUSTRALIA: MAIN TB/LTBI INSTITUTIONS
  • TABLE 127 AUSTRALIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 128 AUSTRALIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 129 AUSTRALIA: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 130 AUSTRALIA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 131 SINGAPORE: MAIN TB/LTBI INSTITUTIONS
  • TABLE 132 SINGAPORE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 133 SINGAPORE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 134 SINGAPORE: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 135 SINGAPORE: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 136 BANGLADESH: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 137 BANGLADESH: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 138 BANGLADESH: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 139 BANGLADESH: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 140 REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 141 REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 142 REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 143 REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 144 EUROPE: MACROINDICATORS FOR LATENT TB TESTING MARKET
  • TABLE 145 EUROPE: LATENT TB TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 146 EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 147 EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 148 EUROPE: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 149 EUROPE: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 150 UK: MAIN TB/LTBI INSTITUTIONS
  • TABLE 151 UK: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 152 UK: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 153 UK: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 154 UK: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 155 FRANCE: MAIN TB/LTBI INSTITUTIONS
  • TABLE 156 FRANCE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 157 FRANCE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 158 FRANCE: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 159 FRANCE: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 160 GERMANY: MAIN TB/LTBI INSTITUTIONS
  • TABLE 161 GERMANY: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 162 GERMANY: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 163 GERMANY: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 164 GERMANY: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 165 SPAIN: MAIN TB/LTBI INSTITUTIONS
  • TABLE 166 SPAIN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 167 SPAIN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 168 SPAIN: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 169 SPAIN: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 170 ITALY: MAIN TB/LTBI INSTITUTIONS
  • TABLE 171 ITALY: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 172 ITALY: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 173 ITALY: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 174 ITALY: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 175 BELGIUM: MAIN TB/LTBI INSTITUTIONS
  • TABLE 176 BELGIUM: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 177 BELGIUM: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 178 BELGIUM: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 179 BELGIUM: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 180 RUSSIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 181 RUSSIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 182 RUSSIA: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 183 RUSSIA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 184 SWEDEN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 185 SWEDEN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 186 SWEDEN: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 187 SWEDEN: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 188 DENMARK: MAIN TB/LTBI INSTITUTIONS
  • TABLE 189 DENMARK: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 190 DENMARK: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 191 DENMARK: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 192 DENMARK: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 193 REST OF EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 194 REST OF EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 195 REST OF EUROPE: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 196 REST OF EUROPE: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 197 LATIN AMERICA: MACROINDICATORS FOR LATENT TB TESTING MARKET
  • TABLE 198 LATIN AMERICA: LATENT TB TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 199 LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 200 LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 201 LATIN AMERICA: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 202 LATIN AMERICA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 203 BRAZIL: MAIN TB/LTBI INSTITUTIONS
  • TABLE 204 BRAZIL: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 205 BRAZIL: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 206 BRAZIL: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 207 BRAZIL: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 208 MEXICO: MAIN TB/LTBI INSTITUTIONS
  • TABLE 209 MEXICO: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 210 MEXICO: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 211 MEXICO: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 212 MEXICO: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 213 REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 214 REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 215 REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 216 REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 217 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 218 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 219 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 220 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 221 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 222 SOUTH AFRICA: MAIN TB/LTBI INSTITUTIONS
  • TABLE 223 SOUTH AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 224 SOUTH AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 225 SOUTH AFRICA: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 226 SOUTH AFRICA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 227 SAUDI ARABIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 228 SAUDI ARABIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 229 SAUDI ARABIA: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 230 SAUDI ARABIA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 231 UAE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 232 UAE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 233 UAE: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 234 UAE: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 235 KUWAIT: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 236 KUWAIT: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 237 KUWAIT: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 238 KUWAIT: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 239 REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 240 REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)
  • TABLE 241 REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 242 REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 243 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
  • TABLE 244 LATENT TB TESTING MARKET: DEGREE OF COMPETITION
  • TABLE 245 LATENT TB TESTING MARKET: TEST TYPE FOOTPRINT
  • TABLE 246 LATENT TB TESTING MARKET: APPLICATION FOOTPRINT
  • TABLE 247 LATENT TB TESTING MARKET: REGION FOOTPRINT
  • TABLE 248 LATENT TB TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
  • TABLE 249 LATENT TB TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
  • TABLE 250 LATENT TB TESTING MARKET: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024
  • TABLE 251 LATENT TB TESTING MARKET: DEALS, JANUARY 2021–SEPTEMBER 2024
  • TABLE 252 QIAGEN: COMPANY OVERVIEW
  • TABLE 253 QIAGEN: PRODUCTS OFFERED
  • TABLE 254 QIAGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–SEPTEMBER 2024
  • TABLE 255 QIAGEN: DEALS, JANUARY 2021–SEPTEMBER 2024
  • TABLE 256 QIAGEN: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024
  • TABLE 257 REVVITY: COMPANY OVERVIEW
  • TABLE 258 REVVITY: PRODUCTS OFFERED
  • TABLE 259 REVVITY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–SEPTEMBER 2024
  • TABLE 260 BEIJING WANTAI BIOPHARMACEUTICAL: COMPANY OVERVIEW
  • TABLE 261 BEIJING WANTAI BIOPHARMACEUTICAL: PRODUCTS OFFERED
  • TABLE 262 SANOFI: COMPANY OVERVIEW
  • TABLE 263 SANOFI: PRODUCTS OFFERED
  • TABLE 264 ENDO: COMPANY OVERVIEW
  • TABLE 265 ENDO: PRODUCTS OFFERED
  • TABLE 266 BIOMÉRIEUX: COMPANY OVERVIEW
  • TABLE 267 BIOMÉRIEUX: PRODUCTS OFFERED
  • TABLE 268 BIOMÉRIEUX: PRODUCT APPROVALS, JANUARY 2021–SEPTEMBER 2024
  • TABLE 269 SD BIOSENSOR: COMPANY OVERVIEW
  • TABLE 270 SD BIOSENSOR: PRODUCTS OFFERED
  • TABLE 271 SD BIOSENSOR: DEALS, JANUARY 2021–SEPTEMBER 2024
  • TABLE 272 LIONEX GMBH: COMPANY OVERVIEW
  • TABLE 273 LIONEX GMBH: PRODUCTS OFFERED
  • TABLE 274 SERUM INSTITUTE OF INDIA: COMPANY OVERVIEW
  • TABLE 275 SERUM INSTITUTE OF INDIA: PRODUCTS OFFERED
  • TABLE 276 ARKRAY: COMPANY OVERVIEW
  • TABLE 277 ARKRAY: PRODUCTS OFFERED
  • TABLE 278 ARKRAY: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024
LIST OF FIGURES
 
  • FIGURE 1 LATENT TB TESTING MARKET: RESEARCH DESIGN
  • FIGURE 2 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 3 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 4 LATENT TB TESTING MARKET: TOP-DOWN APPROACH
  • FIGURE 5 LATENT TB TESTING MARKET: DATA TRIANGULATION
  • FIGURE 6 LATENT TB TESTING MARKET: STUDY ASSUMPTIONS
  • FIGURE 7 LATENT TB TESTING MARKET, BY TEST TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 8 LATENT TB TESTING MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 9 LATENT TB TESTING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 10 LATENT TB TESTING MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 11 INCREASING PREVALENCE OF LATENT TB AND GROWING FINANCIAL SUPPORT FOR TB CONTROL TO DRIVE MARKET
  • FIGURE 12 IGRA WILL CONTINUE TO DOMINATE MARKET TILL 2029
  • FIGURE 13 PEOPLE LIVING WITH HIV SEGMENT TO HOLD LARGEST MARKET SHARE
  • FIGURE 14 DIAGNOSTIC LABORATORIES SEGMENT TO RETAIN DOMINANT MARKET SHARE TILL 2029
  • FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH
  • FIGURE 16 LATENT TB TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17 PATENT ANALYSIS FOR LATENT TB TESTS (JANUARY 2014–DECEMBER 2023)
  • FIGURE 18 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • FIGURE 19 LATENT TB TESTING MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 20 LATENT TB TESTING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 21 LATENT TB TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LATENT TB TESTS
  • FIGURE 23 KEY BUYING CRITERIA FOR LATENT TB TESTS
  • FIGURE 24 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 25 DEALS AND FUNDING IN LATENT TB TESTING MARKET
  • FIGURE 26 MARKET POTENTIAL OF AI TO ENHANCE R&D IN LATENT TB TESTING MARKET
  • FIGURE 27 NORTH AMERICA: LATENT TB TESTING MARKET SNAPSHOT
  • FIGURE 28 ASIA PACIFIC: LATENT TB TESTING MARKET SNAPSHOT
  • FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN LATENT TB TESTING MARKET (2021–2023)
  • FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LATENT TB TESTING MARKET (2023)
  • FIGURE 31 NORTH AMERICA: MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
  • FIGURE 32 EUROPE: MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
  • FIGURE 33 ASIA PACIFIC: MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
  • FIGURE 34 LATENT TB TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 35 LATENT TB TESTING MARKET: COMPANY FOOTPRINT
  • FIGURE 36 LATENT TB TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 37 EV/EBITDA OF KEY VENDORS
  • FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 39 BRAND COMPARISON FOR IGRA
  • FIGURE 40 QIAGEN: COMPANY SNAPSHOT (2023)
  • FIGURE 41 REVVITY: COMPANY SNAPSHOT (2023)
  • FIGURE 42 BEIJING WANTAI BIOPHARMACEUTICAL: COMPANY SNAPSHOT (2023)
  • FIGURE 43 SANOFI: COMPANY SNAPSHOT (2023)
  • FIGURE 44 ENDO: COMPANY SNAPSHOT (2023)
  • FIGURE 45 BIOMÉRIEUX: COMPANY SNAPSHOT (2023)
  • FIGURE 46 SD BIOSENSOR: COMPANY SNAPSHOT (2023)

 

The study involved major activities in estimating the current market size for the latent TB testing market. Exhaustive secondary research was done to collect information on the latent TB testing industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the latent TB testing market.

The four steps involved in estimating the market size are

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

The following is a breakdown of the primary respondents:

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME DESIGNATION
QIAGEN General Manager
Revvity Area Sales Manager

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the latent TB testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the latent TB testing market have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

The research methodology used to estimate the market size includes the following:

Data Triangulation

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Latent tuberculosis testing refers to diagnosing the infection by detecting an immune response to Mycobacterium tuberculosis antigens using either the tuberculin skin test (TST) or interferon-gamma release assays (IGRAs). These tests help identify dormant tuberculosis infections in individuals without active symptoms.

Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department  
  • R&D Department

Report Objectives

  • To define, describe, segment, and forecast the global latent TB testing market, by test type, application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall latent TB testing market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Middle East & Africa, and Latin America
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
  • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

 

Previous Versions of this Report

"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Latent TB Testing Market

DMCA.com Protection Status